FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Matthias Schwenkglenks

Research Profile

Geographic Areas

Activities & Behaviors

Cost Benefit Analysis

Disorders

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Lea Bollhalder; Alena M Pfeil; Yuki Tomonaga; Matthias Schwenkglenks
A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation.
Stephan R Vavricka; Gerhard Rogler; Ekaterina Safroneeva; Alain M Schoepfer; Matthias Schwenkglenks; Rita Achermann
A shift from oral to intravenous iron supplementation therapy is observed over time in a large swiss cohort of patients with inflammatory bowel disease.
Ruth Pettengell; Beatriz Pujol; Francesca Gaia Rossi; Matthias Schwenkglenks; Antonio Salar Silvestre; Gregor Verhoef; Tracey Wheeler; Ulrich Duehrsen; Pieternella J Lugtenburg; Corinne Haioun
Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Matthias Schwenkglenks (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lea Bollhalder; Alena M Pfeil; Yuki Tomonaga; Matthias Schwenkglenks
A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation.
Clinical nutrition (Edinburgh, Scotland) 2013;32(2):213-23.
2013: Stephan R Vavricka; Gerhard Rogler; Ekaterina Safroneeva; Alain M Schoepfer; Matthias Schwenkglenks; Rita Achermann
A shift from oral to intravenous iron supplementation therapy is observed over time in a large swiss cohort of patients with inflammatory bowel disease.
Inflammatory bowel diseases 2013;19(4):840-6.
2013: Ruth Pettengell; Beatriz Pujol; Francesca Gaia Rossi; Matthias Schwenkglenks; Antonio Salar Silvestre; Gregor Verhoef; Tracey Wheeler; Ulrich Duehrsen; Pieternella J Lugtenburg; Corinne Haioun
Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.
Hematology (Amsterdam, Netherlands) 2013;18(1):26-9.
2012: Antonio Salar; Matthias Schwenkglenks; Gregor Verhoef; Ruth Pettengell; Francesca G Rossi; Pamela Bacon; Kate Bendall; Ulrich Duehrsen; Corinne Haioun; Ulrich Jaeger; Hans E Johnsen; Pieternella J Lugtenburg
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.
Leukemia research 2012;36(5):548-53.
2012: Hans E Johnsen; Pieternella J Lugtenburg; Ruth Pettengell; Francesca G Rossi; Antonio Salar; Matthias Schwenkglenks; Gregor Verhoef; Kate Bendall; Corrine Haioun; Ulrich Jaeger; Ulrich Duehrsen
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.
Leukemia & lymphoma 2012;53(5):982-4.
2012: Matthias Schwenkglenks; Thomas D Szucs; Toby J Toward; Daniel J Blackman; Stephanie Plent; Andreas Baumbach
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.
Heart (British Cardiac Society) 2012;98(7):544-51.
2012: Patricia Blank; Matthias Schwenkglenks; Thomas D Szucs
The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly.
Human vaccines & immunotherapeutics 2012;8(3):328-35.
2012: Ruth Pettengell; Francesca G Rossi; Matthias Schwenkglenks; Antonio Salar Silvestre; Zsolt Szabo; Hans E Johnsen; Kate Bendall; Ulrich Dührsen; Hans E Johnson; Pieternella J Lugtenburg; Ulrich Jaeger
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2012;20(3):647-52.
2012: K Lippuner; S Grifone; A W Popp; P Schwab; Matthias Schwenkglenks; C Senn; Romain Perrelet
Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(3):829-39.
2012: Klazien Matter-Walstra; Bernhard Pestalozzi; Markus Joerger; Ursula Kühnel; Thomas D Szucs; Matthias Schwenkglenks
Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(1):65-71.
2011: Lars Egevad; Andrew J Evans; Rainer Grobholz; Glen Kristiansen; Cord Langner; Gina Lockwood; Antonio Lopez-Beltran; Rodolfo Montironi; Pedro Oliveira; Matthias Schwenkglenks; Ben Vainer; Murali Varma; Vincent Verger; Ferran Algaba; Daniel M Berney; Liliane Boccon-Gibod; Eva Compérat; Philippe Camparo
Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.
Virchows Archiv : an international journal of pathology 2011;459(2):175-82.
2011: Ruth Pettengell; Matthias Schwenkglenks
Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups.
Leukemia & lymphoma 2011;52(6):1133-6.
2011: Corinne Haioun; Antonio Salar; Ruth Pettengell; Ulrich Duehrsen; Gregor Verhoef; Matthias Schwenkglenks; Ulrich Jaeger; Lisa Hamilton; Beatriz Pujol; Hans Erik Johnsen; Francesca Gaia Rossi; Pieternella Johanna Lugtenburg
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study.
Leukemia & lymphoma 2011;52(5):796-803.
2011: Matthias Schwenkglenks; Ruth Pettengell; Christian Jackisch; Robert Paridaens; Manuel Constenla; André Bosly; Thomas D Szucs; Robert Leonard
Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19(4):483-90.
2011: Sibylle Loibl; Tomas Skacel; Valentina Nekljudova; Hans Joachim Lück; Matthias Schwenkglenks; Thomas Brodowicz; Christoph Zielinski; Gunter von Minckwitz
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
BMC cancer 2011;11():131.
2011: Yuki Tomonaga; Felix Gutzwiller; Thomas F Lüscher; Walter F Riesen; Markus Hug; Albert Diemand; Matthias Schwenkglenks; Thomas D Szucs
Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial.
BMC family practice 2011;12():12.
2010: Patricia R Blank; Matthias Schwenkglenks; Holger Moch; Thomas D Szucs
Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Breast cancer research and treatment 2010;124(2):497-507.
2010: Matti Aapro; Matthias Schwenkglenks; Gary H Lyman; Antonio Lopez Pousa; Susan Lawrinson; Tomas Skacel; Pamela Bacon; Gunter von Minckwitz
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.
Critical reviews in oncology/hematology 2010;74(3):203-10.
2010: Michel Romanens; Franz Ackermann; J David Spence; Roger Darioli; Nicolas Rodondi; Roberto Corti; Georg Noll; Matthias Schwenkglenks; Michael Pencina
Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2010;17(1):18-23.
2010: Matthias Schwenkglenks; Ruth Pettengell; Thomas D Szucs; Eva Culakova; Gary H Lyman
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
Journal of hematology & oncology 2010;3():27.
2009: Patricia Blank; Matthias Schwenkglenks; Thomas D Szucs
Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons.
Infection 2009;37(5):390-400.
2009: Patricia Blank; Matthias Schwenkglenks; Thomas D Szucs
Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.
The Journal of infection 2009;58(6):446-58.
2009: Michel Romanens; Franz Ackermann; Michael Abay; Thomas D Szucs; Matthias Schwenkglenks
Agreement of Swiss-adapted international and European guidelines for the assessment of global vascular risk and for lipid lowering interventions.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2009;23(3):249-54.
2009: Konstantin Dedes; Klazien Matter-Walstra; Matthias Schwenkglenks; Bernhard C Pestalozzi; Daniel Fink; Peter Brauchli; Thomas D Szucs
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.
European journal of cancer (Oxford, England : 1990) 2009;45(8):1397-406.
2009: Ruth Pettengell; André Bosly; Thomas D Szucs; Christian Jackisch; Robert Leonard; Robert Paridaens; Manuel Constenla; Matthias Schwenkglenks
Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.
British journal of haematology 2009;144(5):677-85.
2008: Ruth Pettengell; Matthias Schwenkglenks; Robert Leonard; André Bosly; Robert Paridaens; Manuel Constenla; Thomas D Szucs; Christian Jackisch
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2008;16(11):1299-309.
2008: Patricia Blank; Andreas Freiburghaus; Matthias Schwenkglenks; Thomas D Szucs
Trends in influenza vaccination coverage rates in the United Kingdom over six seasons from 2001-2 to 2006-7.
Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin 2008;13(43):.
2008: Nicole Blijlevens; Matthias Schwenkglenks; Pamela Bacon; Alessandra D'Addio; Hermann Einsele; Johan Maertens; Dietger Niederwieser; Werner Rabitsch; Ann Roosaar; Tapani Ruutu; Harry Schouten; Rebecca Stone; Samuel Vokurka; Barry Quinn; Shaun McCann
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1519-25.
2008: Patricia Blank; Matthias Schwenkglenks; Thomas D Szucs
Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons.
BMC public health 2008;8():272.
2007: Matthias Schwenkglenks; Kurt Lippuner
Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2007;18(11):1481-91.
2007: Matthias Schwenkglenks
Self-treatment and self-medication of Swiss primary care physicians: a cause for concern?
Swiss medical weekly 2007;137(7-8):105-6.
2006: Matthias Schwenkglenks; Christian Jackisch; Manuel Constenla; Joseph N Kerger; Robert Paridaens; Leo Auerbach; André Bosly; Ruth Pettengell; Thomas D Szucs; Robert Leonard
Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2006;14(9):901-9.
2006: Thomas D Szucs; Majbrit V Holm; Matthias Schwenkglenks; Zefeng Zhang; William S Weintraub; Michel Burnier; Paul Erne
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2006;20(3):193-204.
2005: Matthias Schwenkglenks; Kurt Lippuner; Hans Jörg Häuselmann; Thomas D Szucs
A model of osteoporosis impact in Switzerland 2000-2020.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2005;16(6):659-71.
2004: Jacques Claude; Christian Schindler; Gabriela M Kuster; Matthias Schwenkglenks; Thomas Szucs; Peter T Buser; Stefan Osswald; Christoph Kaiser; Christoph Grädel; Werner Estlinbaum; Peter Rickenbacher; Matthias Pfisterer
Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME).
European heart journal 2004;25(24):2195-203.
2004: Menga S Sandoz; Silvia M Ess; Gérald W Keusch; Matthias Schwenkglenks; Thomas D Szucs
Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.
Swiss medical weekly 2004;134(31-32):448-58.
2004: Irmgard Schmitt-Koopmann; Matthias Schwenkglenks; Giatgen A Spinas; Thomas D Szucs
Direct medical costs of type 2 diabetes and its complications in Switzerland.
European journal of public health 2004;14(1):3-9.
2004: Matthias Schwenkglenks; Urs A Marbet; Thomas D Szucs
Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based study.
Sozial- und Präventivmedizin 2004;49(1):51-61.
2003: Thomas D Szucs; Matthias Schwenkglenks; K Berger; K Karsch
[Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
Zeitschrift für Kardiologie 2003;92(3):236-44.
2002: Emina Sokolovic; Daniel Schmidlin; Edith R Schmid; M Turina; C Ruef; Matthias Schwenkglenks; Thomas D Szucs
Determinants of costs and resource utilization associated with open heart surgery.
European heart journal 2002;23(7):574-8.
2002: Gieri Cathomas; Paul Erne; Matthias Schwenkglenks; Thomas D Szucs
The economic efficiency of amlodipine in the treatment of coronary atherosclerosis--an analysis based on the PREVENT study.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2002;16(1):61-6.
2000: Thomas D Szucs; Matthias Schwenkglenks; B Paschen; F Follath
[Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study].
Medizinische Klinik (Munich, Germany : 1983) 2000;95(12):663-71.
2000: Thomas D Szucs; Matthias Schwenkglenks; W Rutishauser
[Economic evaluation of different treatment strategies in patients with stable angina pectoris or asymptomatic myocardial ischemia on basis of results from the Asymptomatic-Cardiac-Ischemia Pilot study (ACIP)].
Medizinische Klinik (Munich, Germany : 1983) 2000;95(1):1-13.